Dai Fukumura, M.D., Ph.D.

Immune checkpoint inhibitors that unleash the immune response to tumor cells have revolutionized cancer treatment. However, this drug is ineffective in many patients, including those with colorectal cancer.New research published in PNAS This, led by researchers at the Massachusetts General Hospital (MGH) and the University of Geneva (UNIGE), provides insights into why some types of colorectal cancer do not respond to immune checkpoint inhibitors and their resistance. Provides a strategy to overcome.

“Colorectal cancer is the second leading cause of cancer-related deaths in the United States and around the world,” said Andrew Workcook, a professor of radiation oncology at MGH and Harvard University School of Medicine (HMS). “The main cause of death in patients with colorectal cancer is the development of liver metastasis, which is the spread of cancer to the liver… Continue reading.

Exercise training may slow tumor growth and improve outcomes for females with breast cancer – especially those treated with immunotherapy drugs – by stimulating naturally occurring immune mechanisms, researchers at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) have found.

Tumors in mouse models of human breast cancer grew more slowly in mice put through their paces in a structured aerobic exercise program than in sedentary mice, and the tumors in exercised mice exhibited an increased anti-tumor immune response.

“The most exciting finding was that exercise training brought into tumors immune cells capable of killing cancer cells known as cytotoxic T lymphocytes (CD8+ T cells) and activated them. With more of these cells, tumors grew more slowly in mice that performed exercise training,” says co-corresponding author Dai Fukumura, MD, PhD, deputy director of the Edwin L. Steele Laboratories in the Department of Radiation Oncology at MGH… Continue reading.

WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Dai Fukumura, M.D., Ph.D., Associate Professor (HMS); Investigator (MGH); Deputy Director of Edwin L. Steele Laboratories (MGH), Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital; Harvard Medical School, to its College of Fellows. Dr. Fukumura was nominated, reviewed, and elected by peers and members of the College of Fellows For outstanding contributions to the development and application of novel intravital microscopy techniques for vascular biology and tumor microenvironment research..